CD274 and non-small cell lung carcinoma: Considering the limitations of indirect treatment comparisons and extrapolations, for first-line treatment in patients with locally advanced or metastatic NSCLC and PD-L1 ⩾50%, cemiplimab monotherapy demonstrated statistically significant improvements in PFS and ORR, comparable OS, and no evidence of differences in Grade 3–5 all-cause AEs, IMAEs, and all-cause DAEs versus pembrolizumab monotherapy.